For years, researchers have been chasing a so-called silver bullet compound that could effectively treat anyone with amyotrophic lateral sclerosis (ALS). Hande Ozdinler, an associate professor of neurology at Northwestern University, thinks that this approach should be reassessed and a different, more nuanced view of ALS treatment should…
FGF21, a hormone that helps cells regulate energy use and respond to stress, may protect muscles and nerve cells from damage related to amyotrophic lateral sclerosis (ALS), slowing disease progression. A study found ALS patients had significantly higher levels of FGF21 in their blood and muscles than healthy controls,…
Researchers identified three forms, or biotypes, of amyotrophic lateral sclerosis (ALS), each with distinct mechanisms that could suggest pathways for biologically specific treatment. A machine learning model was able to classify people with ALS into these three groups using demographic and disease-related information. “The machine learning model we developed,…
Immune checkpoint proteins — proteins that help regulate immune response — were elevated on T-cells and in the blood of people with amyotrophic lateral sclerosis (ALS), a small study found, suggesting they may play a role in how the disease develops. The increases were associated with more severe…
The ALS Network is honoring actor Eric Dane as its Advocate of the Year, granting the former TV doctor the annual award in recognition of his efforts and commitment to raising awareness and support for people living with amyotrophic lateral sclerosis (ALS). The award will be presented at…
Patient enrollment is complete in a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast), an investigational oral therapy developed by Medicinova to treat amyotrophic lateral sclerosis (ALS). The COMBAT-ALS (NCT04057898) trial is testing whether MN-166 can safely slow ALS progression in 234 adults with ALS, ages 18 to…
Coya Therapeutics has launched a Phase 2 clinical trial of COYA 302 — an experimental therapy combining the signaling molecule IL-2 with CTLA4-Ig, also known as abatacept — to evaluate whether its use can slow disease progression in adults with amyotrophic lateral sclerosis (ALS) over a six-month period.
In adults with amyotrophic lateral sclerosis (ALS) who have slower disease progression, the stem cell therapy Neuronata-R (lenzumestrocel) — conditionally approved in South Korea for treating ALS — was found to help preserve daily function and breathing capacity, while also reducing signs of nerve damage and inflammation. That’s according to…
The UCLA ALS Clinic and Research Center has been officially designated a Certified Treatment Center of Excellence for people in the U.S. with amyotrophic lateral sclerosis (ALS) — making it the 100th center nationwide to receive such recognition. This designation, awarded by the ALS Association, means the…
Nonprofit I AM ALS has teamed up with actor Eric Dane to launch Push for Progress, a three-year campaign focused on accelerating research on amyotrophic lateral sclerosis (ALS), expanding access to treatments, and securing $1 billion in federal funding. Dane, best known for his roles in “Grey’s…
